Abstracts tagged "Cardiovascular"

Abstract Number: 0693 • ACR Convergence 2023
Comparison of the Cardiovascular Risk in Patients with Vasculitis and Diabetes Mellitus
Ana Belen Arevalo¹, Harshvardhan Zala², Andrea Ramirez Gomez¹ and Kichul Ko³, ¹University of Chicago, Chicago, IL, ²Indiana University School of Medicine, Indianapolis, IN, ³The University of Chicago, Chicago, IL
Background/Purpose: Cardiovascular disease (CVD) has been reported as the most common cause of death in ANCA-associated vasculitis (AAV)1,2. Systemic inflammation, in addition to traditional risk…
Abstract Number: 1060 • ACR Convergence 2023
Impact of Troponin Monitoring on Cardiac Outcomes in Patients Receiving Immune Checkpoint Inhibitors
Maja Ivanovic¹, Antonia Chan², Miguel Franquiz¹, Sidra Xu³, Carissa Lee³, Muhammad Fazal⁴, Jonathan You¹, Ronald Witteles⁴, Joel Neal⁵, Sean Wu⁴, Sarah Waliany¹ and Han Zhu⁴, ¹Department of Medicine, Stanford University, Stanford, CA, ²Stanford Medical School, Stanford, CA, ³Stanford University, Stanford, CA, ⁴Department of Cardiology, Stanford University, Stanford, CA, ⁵Department of Oncology, Stanford University, Stanford, CA
Background/Purpose: Immune checkpoint inhibitors (ICI) are an increasingly used form of anti-cancer therapy, but they have been associated with a range of cardiac immune-related adverse…
Abstract Number: 1327 • ACR Convergence 2023
Effects of Long-Term Low Dose Glucocorticoid Treatment for Rheumatoid Arthritis on Body Weight and Blood Pressure: A Pooled Analysis of Individual Patient Data from Five Randomised Trials
Andriko Palmowski¹, Sabrina Mai Nielsen², Zhivana Boyadzhieva³, Linda Hartman⁴, Judith Oldenkott⁵, Björn Svensson⁶, Ingiäld Hafström⁷, Siegfried Wassenberg⁸, Ernest Choy⁹, John Kirwan¹⁰, Robin Christensen¹¹, Maarten Boers¹² and Frank Buttgereit¹³, ¹Charité - Universitätsmedizin Berlin, Berlin, Germany, ²The Parker Institute, Bispebjerg and Frederiksberg Hospital, Copenhagen, Denmark, ³Charité Universitatsmedizine - Berlin, Berlin, Germany, ⁴Amsterdam University Medical Centers, Amsterdam, Netherlands, ⁵Charite - University Medicine Berlin, Berlin, Germany, ⁶Lund University, Lund, Sweden, ⁷Karolinska Institutet, Stockholm, Sweden, ⁸Rheumazentrum Ratingen, Ratingen, Germany, ⁹Section of Rheumatology, Cardiff University, Cardiff, United Kingdom, ¹⁰University of Bristol, Bristol, United Kingdom, ¹¹Musculoskeletal Statistics Unit, The Parker Institute, Copenhagen, Denmark, ¹²Amsterdam UMC, Vrije Universiteit, Amersfoort, Netherlands, ¹³Charité Universitätsmedizin, Dept. Rheumatology, Berlin, Germany
Background/Purpose: High-dose glucocorticoids (GCs) can cause weight gain and hypertension. It is unclear whether GCs at ≤7.5mg/day prednisone equivalent ("low dose"), administered for rheumatoid arthritis…
Abstract Number: 1798 • ACR Convergence 2023
Association Between Knee Osteoarthritis and Mortality: A Serial Propensity Score-matched Cohort Study
Sunggun Lee¹, Minkyoung Oh², Mi-Yeong Kim³, Minyoung Her¹ and Seong-Ho Kim¹, ¹Department of Internal Medicine, Haeundae Paik Hospital, Inje University College of Medicine, Busan, South Korea, ²Department of pharmacology, Inje University College of Medicine, Busan, South Korea, ³Department of Internal Medicine, Busan Paik Hospital, Inje University College of Medicine, Busan, South Korea
Background/Purpose: The association between symptomatic knee osteoarthritis (OA) and higher cardiovascular disease (CVD) mortality is well established; however, findings from previous studies that utilized regression…
Abstract Number: 2133 • ACR Convergence 2023
Cardiovascular Risk Factors Are Associated with Discontinuation of Advanced Therapies Due to Treatment Failure in Rheumatoid Arthritis: Results from the OBRI
Samar Aboulenain¹, Xiuying Li², Mohammad Movahedi³, Claire Bombardier¹ and Bindee Kuriya¹, ¹University of Toronto, Toronto, ON, Canada, ²Toronto General Hospital, Toronto, ON, Canada, ³Toronto General Hospital Research Institute, University Health Network, Toronto, ON, Canada
Background/Purpose: Cardiovascular (CVD) comorbidity can impact overall RA care. We demonstrated that CVD risk factors were associated with higher disease activity and disability. Here, we…
Abstract Number: 0233 • ACR Convergence 2023
Impaired Anti-oxidant Function of HDL and Its Associated Protein, Paraoxonase-1, in Patients with Gout
John FitzGerald¹, Christina Charles-Schoeman², Veena Ranganath³, Ani Shahbazian⁴, Jennifer Wang¹ and Maureen McMahon⁵, ¹University of California Los Angeles, Los Angeles, CA, ²UCLA Medical Center, Santa Monica, CA, ³David Geffen School of Medicine, UCLA, Los Angeles, CA, ⁴UCLA Rheumatology, Los Angeles, CA, ⁵UCLA David Geffen School of Medicine, Los Angeles, CA
Background/Purpose: Longitudinal cohorts have described the association between gout and cardiovascular disease (CVD), while other cohort and interventional studies (CANTOS) have shown the impact of…
Abstract Number: 0494 • ACR Convergence 2023
Levels of Atherosclerotic Index of Plasma and Triglyceride Glucose Index in Patients with Psoriatic Arthritis and Carotid Plaque
Dionicio A. Galarza-Delgado¹, Iris Colunga¹, José Ramón Azpiri-López¹, Valeria Gonzalez-Gonzalez², Rosa Arvizu-Rivera³, Victor Beltran⁴, Angel Arias Peralta⁵ and Jesus Alberto Cardenas-De la Garza⁶, ¹Hospital Universitario UANL, Monterrey, Mexico, ²Universidad Autónoma de Nuevo León, Monterrey, Mexico, ³Hospital Universitario "Dr. José Eleuterio Gonzalez", Escobedo, Mexico, ⁴Rheumatology Service Hospital Universitario "Dr. José Eleuterio González", Monterrey, Mexico, ⁵Medicine Faculty, Universidad Autonoma De Nuevo Leon, Monterrey, Mexico, ⁶Hospital Universitario "Dr. José Eleuterio González", San Nicolas, Mexico
Background/Purpose: Triglyceride Glucose Index (TyG) is a surrogate marker positively correlated with atherosclerotic burden in patients with psoriatic arthritis (PsA). Atherosclerotic index of plasma (AIP)…
Abstract Number: 0695 • ACR Convergence 2023
Impact and Cardiovascular Outcomes of Large Vessel Vasculitis in Atrial Fibrillation Hospitalization: A Nationwide Inpatient Database Study
Sabahat Usmani¹, Yanint Raksadawan¹, Amro Taha¹, Harigopal Sandhyavenu¹, Jalpan Patel¹, Thatiana Schulze Goni¹, Hafiz Muhammad Waqar Younas¹ and Irisha Badu², ¹Weiss Memorial Hospital, Chicago, IL, ²Onslow Memorial Hospital, Jacksonville, FL
Background/Purpose: Atrial fibrillation is the most commonly treated cardiac arrhythmia, associated with significant morbidity and mortality. Recent research is suggestive that autoimmunity and inflammation might…
Abstract Number: 1111 • ACR Convergence 2023
Urate-Lowering Therapy Is Associated with a Reduced Risk of Arrhythmias: A Systematic Review and Meta-analysis
Palapun Waitayangkoon¹, Tatchaya Kanthajan² and Thiratest Leesutipornchai³, ¹MetroWest Medical Center, Framingham, MA, ²Srinakharinwirot University, Bangkok, Thailand, ³University of Hawaii, Honolulu, HI
Background/Purpose: Recent studies have suggested that hyperuricemia is significantly associated with an increased prevalence of atrial and ventricular arrhythmias and urate-lowering therapy (ULT) may provide…
Abstract Number: 1337 • ACR Convergence 2023
Effect of Tofacitinib Therapy on Angiotensin Converting Enzyme Activity in Rheumatoid Arthritis
Dorottya Kacsándi, Miklós Fagyas, Ágnes Horváth, Edit Végh, Anita Pusztai, Monika Czókolyová, Boglárka Soós, Attila Ádám Szabó, Attila Hamar, Zsófia Pethő, Nóra Bodnár, György Kerekes, Katalin Hodosi, Szilvia Szamosi, Gabriella Szücs, Zoltán Papp and Zoltán Szekanecz, University of Debrecen, Faculty of Medicine, Debrecen, Hungary
Background/Purpose: The Renin-Angiotensin-Aldosterone system (RAAS) has been implicated in the regulation of the cardiovascular system and linked to rheumatoid arthritis (RA). Little information has become…
Abstract Number: 1799 • ACR Convergence 2023
Association of Pregabalin vs Gabapentin with Incident Congestive Heart Failure in Patients with Non-Cancer Pain
Elizabeth Park¹, Laura Daniel², Alyson Dickson³, Meghan Corriere⁴, Puran Nepal⁵, Kathi Hall⁴, Dale Plummer⁴, William Dupont⁴, Katherine Murray⁴, C. Michael Stein³, Wayne Ray⁴ and Cecilia Chung⁶, ¹Columbia University Irving Medical Center, New York, NY, ²University of Miami, Nashville, TN, ³Vanderbilt University Medical Center, Nashville, TN, ⁴Vanderbilt University, Nashville, TN, ⁵University of Miami Health System and Miller School of Medicine, Miami, FL, ⁶University of Miami, Miami, FL
Background/Purpose: Chronic pain affects 30% of all patients in developed countries, accounting for up to 35% of prescriptions in acute care settings. Non-opioid pain medications…
Abstract Number: 2141 • ACR Convergence 2023
Glucocorticoid Treatment in Early Rheumatoid Arthritis Is Associated with Increased Proprotein Convertase Subtilisin/kexin Type 9 (PCSK9) Levels: A Post-hoc Analysis of a Randomized Controlled Trial (NORD-STAR)
Kristina Lend¹, Jos W.R. Twisk², Nupur Kumar³, John Lampa⁴, Anna Rudin⁵, Merete Hetland⁶, Till Uhlig⁷, Dan Nordstrom⁸, Mikkel Østergaard⁹, Marte Schrumpf Heiberg¹⁰, Espen A Haavardsholm¹⁰, Bjorn Gudbjornsson¹¹, Tuulikki Sokka-Isler¹², Gerdur Maria Grondal¹³, Kim Hørslev-Petersen¹⁴, Michael Nurmohamed², Ronald van Vollenhoven² and Johan Frostegård³, ¹Amsterdam UMC, Karolinska Institute, Stockholm, Sweden, ²Amsterdam University Medical Centers, Amsterdam, Netherlands, ³Karolinska Institutet, Stockholm, Sweden, ⁴Stockholm County, Hãsselby, Sweden, ⁵Department of Rheumatology and Inflammation Research, Institute of Medicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden, ⁶Copenhagen Center for Arthritis Research, Rigshospitalet, Copenhagen, Denmark, ⁷Center for Treatment of Rheumatic and Musculoskeletal Diseases (REMEDY), Diakonhjemmet Hospital, Oslo, Norway, ⁸Helsinki University Hospital, Helsinki, Finland, ⁹Copenhagen Center for Arthritis Research, Center for Rheumatology and Spine Diseases, Centre for Head and Orthopaedics, Rigshospitalet; University of Copenhagen, Copenhagen, Denmark, ¹⁰Diakonhjemmet Hospital, Oslo, Norway, ¹¹Centre for Rheumatology Research, University Hospital, Reykjavik, Iceland, ¹²Jyvaskyla Central Hospital, Jyväskylä, Finland, ¹³Department for Rheumatology, Landspitali University Hospital, Reykjavik, Iceland, ¹⁴University of Southern Denmark, Odense, Denmark
Background/Purpose: Rheumatoid arthritis (RA) is associated with an elevated risk for developing atherosclerotic cardiovascular disease (CVD). Proprotein convertase subtilisin/kexin type 9 (PCSK9) is a key…
Abstract Number: 0236 • ACR Convergence 2023
Treatment-emergent Major Adverse Cardiovascular and Thromboembolic Events Were Infrequent During Pegloticase Therapy: Pooled Clinical Trial Findings
orrin Troum¹, Mai Duong², Katie Obermeyer², Lissa Padnick-Silver² and Brian LaMoreaux², ¹University of Southern California Keck School of Medicine and Providence Saint John's Health Center, Santa Monica, CA, ²Horizon Therapeutics, Deerfield, IL
Background/Purpose: Gout is associated with high comorbidity, including cardiovascular (CV), metabolic, and renal disease,1 with even higher burden in uncontrolled gout patients (pts).2 CV (myocardial…
Abstract Number: 0496 • ACR Convergence 2023
Higher Values of Atherogenic Index of Plasma Are Correlated with Increased Cardiovascular Risk in Patients with Psoriatic Arthritis
Valeria Gonzalez-Gonzalez¹, Iris Colunga², Dionicio A. Galarza-Delgado², José Ramón Azpiri-López², Rosa Arvizu-Rivera³, Jesus Alberto Cardenas-De la Garza⁴, Victor Beltran⁵ and Angel Arias Peralta⁶, ¹Universidad Autónoma de Nuevo León, Monterrey, Mexico, ²Hospital Universitario UANL, Monterrey, Mexico, ³Hospital Universitario "Dr. José Eleuterio Gonzalez", Escobedo, Mexico, ⁴Hospital Universitario "Dr. José Eleuterio González", San Nicolas, Mexico, ⁵Rheumatology Service Hospital Universitario "Dr. José Eleuterio González", Monterrey, Mexico, ⁶Medicine Faculty, Universidad Autonoma De Nuevo Leon, Monterrey, Mexico
Background/Purpose: The atherogenic index of plasma (AIP) is a predictor of atherosclerosis and coronary heart disease. In patients with systemic lupus erythematosus and rheumatoid arthritis,…
Abstract Number: 0703 • ACR Convergence 2023
Cardiovascular Disease-Related Mortality in Primary Systemic Vasculitis
Alicia Rodriguez-Pla, Sierra Pacific Arthritis and Rheumatology Centers, Fresno, CA
Background/Purpose: Cardiovascular disease (CVD) is the leading cause of death in patients with the most common subtypes of primary systemic vasculitides. We aimed to estimate…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].